Stocks›Healthcare›ANIP

ANIP

ANI PHARMACEUTICALS, INC

NasdaqResearch view

$74.00−0.05%

Sep 25 close · 1D EOD · Databento

HealthcarePharmaceutical PreparationsSmall-capSEC EDGAR FY 2025-12-31

What happened

Daily closes · dots are Wire stories

1 story has a settled receipt so far (1 on the Wire). The record starts speaking at three.

What’s next

Expected around early November, going by its own filing history. The company has not announced a date yet. Its matching report came Nov 7, 2025, before the open.

Last report

Aug 7, 2026−5.30%

before the open

Last 4, next close

median 3.33% either way

up 0 of 4

Every report since 2025 →

DateEventSourceNext close

Aug 7ANI Pharmaceuticals Q2 2026 slides: record results, gout expansion underwayInvesting.comInvesting.com−5.30%
Aug 7Earnings release, before the open · 8-KSEC EDGARSEC EDGAR ↗−5.30%

Next close = the first close after the event against the close before it. Prior-session closes only; not a call, not advice.

Big days · last year

Daily closes · Databento EOD

12 big days: a close more than 3.67% from the one before, three times ANIP’s median day (1.22%). On 1 of 12, its largest peers moved the same way at least half as far. We show what we hold, never a cause.

Shaded: since our stories began, Jun 10, 2026

12Sep 23, 2026
Sep 23, 2026Nothing in our recordNo ANIP story, brief or results filing in our record that dayGroup −0.8% did not move with it
−0.8% did not move with itMRK −1.9 · LLY −1.6 · ABBV −0.1 · JNJ −0.0
−4.47%
11Aug 7, 2026
Aug 7, 2026Results · 1 storyANI Pharmaceuticals Q2 2026 slides: record results, gout expansion underway · Investing.comGroup +0.5% did not move with it
+0.5% did not move with itABBV +0.9 · JNJ +0.9 · LLY −0.5 · MRK +0.2
−5.30%
10Jun 4, 2026
Jun 4, 2026Before our storiesGroup +4.0% moved the same way
+4.0% moved the same wayMRK +4.8 · LLY +4.3 · ABBV +3.6 · JNJ +2.2
+5.28%
9May 11, 2026
May 11, 2026Before our storiesGroup +0.3% did not move with it
+0.3% did not move with itLLY +1.9 · ABBV +0.6 · MRK −0.1 · JNJ +0.1
−3.85%
8Apr 6, 2026
Apr 6, 2026Before our storiesGroup −0.9% did not move with it
−0.9% did not move with itABBV −1.0 · LLY −0.9 · JNJ −0.8 · MRK −0.0
+4.03%
7Mar 31, 2026
Mar 31, 2026Before our storiesGroup +1.9% did not move with it
+1.9% did not move with itLLY +3.7 · ABBV +2.0 · MRK +1.9 · JNJ +0.8
+4.33%
6Mar 12, 2026
Mar 12, 2026Before our storiesGroup −0.7% did not move with it
−0.7% did not move with itLLY −2.3 · ABBV −1.0 · JNJ −0.4 · MRK −0.3
−4.98%
5Feb 27, 2026
Feb 27, 2026ResultsThe first close after a results filing (SEC 8-K, Item 2.02)Group +3.1% did not move with it
+3.1% did not move with itMRK +3.8 · ABBV +3.3 · LLY +2.9 · JNJ +2.0
−4.21%
4Feb 11, 2026
Feb 11, 2026Before our storiesGroup +0.2% did not move with it
+0.2% did not move with itMRK +1.8 · JNJ +1.1 · LLY −1.0 · ABBV −0.7
−4.58%
3Jan 12, 2026
Jan 12, 2026Before our storiesGroup +0.8% did not move with it
+0.8% did not move with itJNJ +2.6 · LLY +1.6 · MRK −1.2 · ABBV −0.0
+10.58%
2Jan 9, 2026
Jan 9, 2026Before our storiesGroup −1.2% did not move with it
−1.2% did not move with itLLY −2.0 · ABBV −1.8 · JNJ −0.7 · MRK −0.4
−5.87%
1Nov 3, 2025
Nov 3, 2025Before our storiesGroup −2.1% did not move with it
−2.1% did not move with itMRK −4.1 · LLY +3.9 · ABBV −2.8 · JNJ −1.4
+3.82%

A story on the same day is not a cause, and a group move is not proof either. Group: LLY, JNJ, ABBV, MRK, the largest companies in ANIP’s SEC industry; “the same way” means the same direction and at least half as far. Prior-session closes only; not a call, not advice.

The numbers · FY2025, filed

SEC EDGAR

Market cap$1.6B

Revenue$883.4M+43.80%

Net income$78.0M

EPS, diluted$3.32+419.20%

Operating margin12.6%

Return on equity14.4%

Debt / equity0.57

All filed figures

Snapshot

SEC EDGAR · FY 2025-12-31

SectorHealthcare

Market Cap$1.6B

Enterprise Value$1.6B

Income$78.0M

Sales$883.4M

Book/sh$22.14

Cash/sh$11.70

Dividend TTM—

Payout2%

Employees—

IPO—

Quick Ratio2.19

Current Ratio2.71

Debt/Eq0.57

EPS (ttm)$3.32

EPS this Y419.2%

EPS past 3/5Y—

Sales past 3/5Y40.8%

EPS Y/Y TTM419.2%

Sales Y/Y TTM43.8%

Shs Outstand24.42M

ROA5.4%

ROE14.4%

ROIC16.1%

Gross Margin—

Oper. Margin12.6%

Profit Margin8.8%

Every figure here is filed with the SEC. Valuation and estimate metrics (P/E, PEG, EV/EBITDA, price targets, forward EPS) are omitted until our market-data feed is licensed for display — we’d rather show fewer numbers than blank ones. Deeper lines (cash flow, balance sheet) below.

Revenue by fiscal year

$216.1M

FY21

$316.4M

FY22

$486.8M

FY23

$614.4M

FY24

$883.4M

FY25

Operating leverage — margins

GrossOperatingNet

Financials, annual · income and cash flowSEC EDGAR · open ▸

Financials — annual

SEC EDGAR · last 5 FY · tap a row to explain it

USD	FY2021	FY2022	FY2023	FY2024	FY2025
Revenue	$216.1M	$316.4M	$486.8M	$614.4M	$883.4M
Gross Profit	—	—	—	—	—
Operating Income	$-39.8M	$-35.3M	$47.0M	$584,000	$111.1M
Net Income	$-43.0M	$-48.0M	$19.0M	$-19.0M	$78.0M
Diluted EPS	$-3.40	$-3.05	$0.85	$-1.04	$3.32
Operating Cash Flow	$3.3M	$-31.2M	$119.0M	$64.0M	$185.2M
Free Cash Flow	$765,000	$-40.1M	$110.1M	$47.8M	$171.4M

Same industry

In the screener →

LLY$1.11T JNJ$653.6B ABBV$467.1B MRK$367.1B ABT$175.3B PFE$163.4B VRTX$133.4B BMY$128.4B

Follow the news. Track the move.

ANIP story timeline

Company updates and connected market context, with the dated price move attached.

Stories

Direct

Sector context/Earnings

Aug 7

ANI Pharmaceuticals Q2 2026 slides: record results, gout expansion underway

ANI Pharmaceuticals reported record Q2 2026 results in presentation slides and said its gout expansion is underway, but the available summary provides no quarterly figures or guidance detail. The setup turns on whether the gout initiative can extend the company’s already strong reported growth without weakening its 8.8% net margin.

Since story

-5.4%

2026-08-07 → 2026-09-25

Investing.com · 52d ago

View both sides →

Follow the news. Track the move.